Where Will Neurocrine Biosciences Be in 5 Years?
2026-10-25 10:45
•Jeff Siegel •The Motley Fool
••• •• Axe Cap view
Neurocrine Biosciences: Strong Growth But Watch Local Rand Impact
Neurocrine’s rapid expansion looks promising, but South African investors should weigh currency risks and pipeline uncertainties.
Neurocrine Biosciences reported strong Q2 revenue, growing 39% year on year, led by Ingrezza and new entrants Crenessity and Vykat XR contributing over $1 billion annually. The company is profitable and eyes major launches for depression and schizophrenia in 2027, which could push revenues to $6-7 billion by 2031. For South African investors, this biotech story is interesting but comes with caveats. The USD/ZAR exchange rate remains volatile, making dollar-based revenue gains from Neurocrine susceptible to rand swings—our currency recently wavered close to R18 per dollar, which can eat into returns. Plus, clinical trial outcomes are binary; failures could derail growth sharply. Local pharma counters aren’t positioned to mimic Neurocrine’s growth, so exposure is via offshore shares or ETFs, increasing currency risk. If the rand weakens further, Neurocrine’s dollar strength may translate well locally, but a rand recovery will compress gains. this is just our opinion and not financial advice
Buy a modest position in Neurocrine via offshore exposure but hedge currency risk where possible. Be ready to trim if pipeline disappointments arise or if USD/ZAR strengthens sharply.
- NBIX
- USD/ZAR
- Clinical trial failures
- Rand volatility impacting local returns
6/10
Neurocrine Biosciences generated $959 million in Q2 2026 revenue with 39% year-over-year growth. The company's flagship drug Ingrezza continues strong double-digit growth, while newer treatments Crenessity and Vykat XR are expanding rapidly. With late-stage clinical trials for depression and schizophrenia treatments expected in 2027, analysts project the company could reach $6-7 billion in annual revenue by 2031, though success depends on pipeline candidates and managing pricing pressures.
Our take is based on reporting first published by The Motley Fool.